A Phase IV Randomised, Double-Blind, Placebo-Controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (RLS) and Sleep Disturbance (MOS Sleep Scale) in Out-Patients With Idiopathic Restless Legs Syndrome

Trial Profile

A Phase IV Randomised, Double-Blind, Placebo-Controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (RLS) and Sleep Disturbance (MOS Sleep Scale) in Out-Patients With Idiopathic Restless Legs Syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2009 Actual patient number (369) added as reported by ClinicalTrials.gov.
    • 10 Jun 2008 Results presented in a Boehringer Ingelheim media release.
    • 17 Apr 2008 Results have been presented at AAN 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top